Metraipolis › archive › dc_e673a455249e

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for extensive-stage small cell lung… — Europe PMC PMID:41164828

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41164828
DOI
10.3389/fpubh.2025.1652917
License (as archived)
solo-consultazione
Archived
2026-11-09T07:36:29.530Z
SHA-256 of the archived text
31dc452ca863b06fcbd5e80eb3265e219c6ce9812951ea822ddc5be39d9cdb21
Stable URL of this page
https://metraipolis.com/documento/dc_e673a455249e

How to cite

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for extensive-stage small cell lung… — Europe PMC PMID:41164828 — Europe PMC (en), https://europepmc.org/article/MED/41164828 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e673a455249e (Metraipolis archive dc_e673a455249e, sha256 31dc452ca863b06fcbd5e80eb3265e219c6ce9812951ea822ddc5be39d9cdb21)
BibTeX
@misc{dce673a455249e,
  title = {Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for extensive-stage small cell lung… — Europe PMC PMID:41164828},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41164828},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e673a455249e; sha256 31dc452ca863b06fcbd5e80eb3265e219c6ce9812951ea822ddc5be39d9cdb21},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41164828. Agents can read the archived copy with the MCP tool read_document.